Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 91%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,306
Total Claims
$1.1M
Drug Cost
855
Beneficiaries
$1,283
Cost/Patient
Risk Score Breakdown 32/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+373%
Opioid rate vs peers
12.2% vs 2.6% avg
+20%
Cost per patient vs peers
$1,283 vs $1,068 avg
+33%
Brand preference vs peers
11.9% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
ML fraud detection score of 91% indicates prescribing patterns with significant similarity to confirmed fraud cases. 18 out of 20 decision trees flagged this provider.
Opioid rate is 373% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
12.2%
Opioid Rate
1,500
Opioid Claims
$27K
Opioid Cost
3.1%
Long-Acting Rate
Brand vs Generic
Brand: 1,455 claims · $843K
Generic: 10,741 claims · $248K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 60 | $78K |
| Semaglutide | 63 | $75K |
| Empagliflozin | 70 | $70K |
| Fluticasone/Umeclidin/Vilanter | 73 | $51K |
| Apixaban | 67 | $46K |
| Rivaroxaban | 51 | $42K |
| Linaclotide | 51 | $33K |
| Tirzepatide | 29 | $32K |
| Mirabegron | 49 | $26K |
| Liraglutide | 21 | $25K |
| Sitagliptin Phosphate | 18 | $23K |
| Dapagliflozin Propanediol | 23 | $23K |
| Sacubitril/Valsartan | 17 | $21K |
| Insulin Glargine,hum.Rec.Anlog | 31 | $20K |
| Icosapent Ethyl | 53 | $19K |
Prescribing Profile
Patient Profile
71
Avg Age
56%
Female
1.75
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About